Studies on the inhibition of feline EGFR in squamous cell carcinoma: Enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors

Cancer Biology and Therapy

Volumn 11, Issue 11, 2011, Pages 927-937

  Bergkvist, Gurå T ^a   Argyle, David J ^a   Pang, Lisa Y ^a   Muirhead, Rhona ^a   Yool, Donald A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Animal model; EGFR; Feline; Gefitinib; Resistance; RNA interference; Squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; RNA;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL KILLING; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; GENETIC TRANSFECTION; HEAD AND NECK CANCER; MEDICAL DOCUMENTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; RADIOSENSITIVITY; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CATS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; CONSERVED SEQUENCE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; QUINAZOLINES; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 79957810205     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.11.15525     Document Type: Article

References (52)

1. Stebbins KE, Morse CC, Goldschmidt MH. Feline oral neoplasia: a ten-year survey. Vet Pathol 1989; 26:121-8.
2. Jakubiak MJ, Siedlecki CT, Zenger E, Matteucci ML, Bruskiewicz KA, Rohn DA, et al. Laryngeal, laryngotracheal and tracheal masses in cats: 27 cases (1998-2003). J Am Anim Hosp Assoc 2005; 41:310-6.
3. Mukaratirwa S, van der Linde-Sipman JS, Gruys E. Feline nasal and paranasal sinus tumors: clinicopathological study, histomorphological description and diagnostic immunohistochemistry of 123 cases. J Feline Med Surg 2001; 3:235-45.
4. Miller MA, Nelson SL, Turk JR, Pace LW, Brown TP, Shaw DP, et al. Cutaneous neoplasia in 340 cats. Vet Pathol 1991; 28:389-95.
5. Kapatkin AS, Maretta SM, Patnaik AK, Burk RL, Matus RE. Mandibular swelling in cats: prospective study of 24 cats. J Am Anim Hosp Assoc 1991; 27:575-80.
6. Northrup NC, Selting KA, Rassnick KM, Kristal O, O'Brien MG, Dank G, et al. Outcomes of cats with oral tumors treated with mandibulectomy: 42 cases. J Am Anim Hosp Assoc 2006; 42:350-60. (Pubitemid 46403560)
7. Fidel JL, Sellon RK, Houston RK, Wheeler BA. A nineday accelerated radiation protocol for feline squamous cell carcinoma. Vet Radiol Ultrasound 2007; 48:482-5. (Pubitemid 47319761)
8. Fox LE, Rosenthal RC, King RR, Levine PB, Vail DM, Helfand SC, et al. Use of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma. Am J Vet Res 2000; 61:791-5. (Pubitemid 30437569)
9. LeBlanc AK, LaDue TA, Turrel JM, Klein MK. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 2004; 45:466-70. (Pubitemid 39430677)
10. Hayes AM, Adams VJ, Scase TJ, Murphy S. Survival of 54 cats with oral squamous cell carcinoma in United Kingdom general practice. J Small Anim Pract 2007; 48:394-9. (Pubitemid 47140949)
11. Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cell Signal 2009; 21:1255-68.
12. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Sasaki C, et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 2004; 10:5684-91. (Pubitemid 39180943)
13. Bukowski JA, Wartenberg D. An alternative approach for investigating the carcinogenicity of indoor air pollution: pets as sentinels of environmental cancer risk. Environ Health Perspect 1997; 105:1312-9. (Pubitemid 28066008)
14. Bertone ER, Snyder LA, Moore AS. Environmental and lifestyle risk factors for oral squamous cell carcinoma in domestic cats. J Vet Intern Med 2003; 17:557-62. (Pubitemid 37465315)
15. Snyder LA, Bertone ER, Jakowski RM, Dooner MS, Jennings-Ritchie J, Moore AS. p53 expression and environmental tobacco smoke exposure in feline oral squamous cell carcinoma. Vet Pathol 2004; 41:209-14. (Pubitemid 38686979)
16. Munday JS, Howe L, French A, Squires RA, Sugiarto H. Detection of papillomaviral DNA sequences in a feline oral squamous cell carcinoma. Res Vet Sci 2009; 86:359-61.
17. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009; 77:400-10.
18. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-37. (Pubitemid 33674041)
19. Thariat J, Yildirim G, Mason KA, Garden AS, Milas L, Ang KK. Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol 2007; 12:99-110. (Pubitemid 46632467)
20. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78:1284-92. (Pubitemid 26303896)
21. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003; 284:122-30. (Pubitemid 36331971)
22. Bergkvist GT, Argyle DJ, Morrison L, MacIntyre N, Hayes A, Yool DA. Expression of epidermal growth factor receptor (EGFR) and Ki67 in feline oral squamous cell carcinomas (FOSCC). Vet Comp Oncol 2011; 9:106-17; DOI: 10.1111/j.1476-5829.2010.00239.x.
23. Looper JS, Malarkey DE, Ruslander D, Proulx D, Thrall DE. Epidermal growth factor receptor expression in feline oral squamous cell carcinomas. Vet Comp Oncol 2006; 4:33-40.
24. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther 2006; 13:464-77.
25. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464:1067-70.
26. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 2004; 3:318-29. (Pubitemid 38499759)
27. Nozawa H, Tadakuma T, Ono T, Sato M, Hiroi S, Masumoto K, et al. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci 2006; 97:1115-24. (Pubitemid 44322563)
28. Chen LF, Cohen EEW, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 2010; 16:2489-95.
29. Bergkvist GT, Yool DA. Epidermal growth factor receptor as a therapeutic target veterinary oncology. Vet Comp Oncol 2011; 9:81-94; DOI: 10.1111/j.1476-5829.2010.00237.x.
30. Nissim A, Chernajovsky Y. Historical development of monoclonal antibody therapeutics. In: Chernajovsky Y, Nissim A. Therapeutic Antibodies: Springer Berlin Heidelberg 2008; 3-18.
31. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7:169-81.
32. Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002; 62:4300-6. (Pubitemid 34827286)
33. Erjala K, Raitanen M, Kulmala J, Grénman R. Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 2007; 133:169-76. (Pubitemid 46144092)
34. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-Agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64:5355-62. (Pubitemid 39006556)
35. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors - impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7:493-507.
36. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28:3801-13.
37. Kittler R, Buchholz F. RNA interference: gene silencing in the fast lane. Semin Cancer Biol 2003; 13:259-65. (Pubitemid 38160917)
38. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27:3944-56. (Pubitemid 351913636)
39. Chaturvedi D, Gao X, Cohen MS, Taunton J, Patel TB. Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene 2009; 28:1187-96.
40. Shtiegman K, Kochupurakkal BS, Zwang Y, Pines G, Starr A, Vexler A, et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 2007; 26:6968-78. (Pubitemid 350014608)
41. Cao C, Huang X, Han Y, Wan Y, Birnbaumer L, Feng GS, et al. Galpha(i1) and Galpha(i3) are required for epidermal growth factor-mediated activation of the Akt-mTORC1 pathway. Sci Signal 2009; 2:17.
42. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-75.
43. Recillas-Targa F. Multiple strategies for gene transfer, expression, knockdown and chromatin influence in mammalian cell lines and transgenic animals. Mol Biotechnol 2006; 34:337-54. (Pubitemid 46220193)
44. Zhang N, Erjala K, Kulmala J, Qiu X, Sundvall M, Elenius K, et al. Concurrent cetuximab, cisplatin and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol 2009; 92:388-92.
45. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006; 12:4103-11. (Pubitemid 44078099)
46. Tannehill-Gregg SH, Levine AL, Rosol TJ. Feline head and neck squamous cell carcinoma: a natural model for the human disease and development of a mouse model. Vet Comp Oncol 2006; 4:84-97.
47. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008; 8:147-56. (Pubitemid 351161319)
48. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009; 15:3856-65.
49. Tannehill-Gregg S, Kergosien E, Rosol TJ. Feline head and neck squamous cell carcinoma cell line: characterization, production of parathyroid hormone-related protein and regulation by transforming growth factor beta. In Vitro Cell Dev Biol Anim 2001; 37:676-83. (Pubitemid 34001118)
50. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007; 2:329-33.
51. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:45-51.
52. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon and breast tumors. Mol Cancer Ther 2006; 5:2676-84. (Pubitemid 44848994)